Biomarkers in dementia with Lewy bodies: A review

International Journal of Geriatric Psychiatry

Volumn 27, Issue 5, 2012, Pages 443-453

  Sinha, Namrta ^a   Firbank, Michael ^a   O'Brien, John T ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

amyloid imaging; biomarkers; CSF; dementia with Lewy bodies; MRI; PET; SPECT

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 6 FLUORODOPA F 18; ALPHA SYNUCLEIN; AMYLOID; FLORBETABEN; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; METHYLAMINO 4' HYDROXYSTILBENE C 11; N (3 FLUOROPROPYL) 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; N METHYL 2 (4 METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE C 11; RADIOPHARMACEUTICAL AGENT; TAU PROTEIN; UNCLASSIFIED DRUG;

CEREBROSPINAL FLUID ANALYSIS; DIFFUSE LEWY BODY DISEASE; DISEASE MARKER; HEART DENERVATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL LOBE;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; LEWY BODY DISEASE; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84859885003     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2749     Document Type: Review

References (101)

1. Aarsland D, Rongve A, Nore SP, et al,. 2008. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord 26 (5): 445-452.
2. Allan LM, Ballard CG, Allen J, et al,. 2007. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry 78: 671-677.
3. Almeida OP, Burton EJ, McKeith I, et al,. 2003. MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 16: 57-63.
4. Andreasen N, Minthon L, Davidsson P, et al,. 2001. Evaluation of CSF tau and CSF-A42 as diagnostic markers for AD in clinical practice. Arch Neurol 58: 373-379.
5. Ballard C, Ziabreva I, Perry R, et al,. 2006. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67: 1931-1934.
6. Barber R, McKeith IG, Ballard C, Gholkar A, O'Brien JT,. 2001. A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: magnetic resonance imaging volumetric study. Dement Geriatr Cogn Disord 12: 198-205.
7. Barber R, McKeith I, Ballard C, O'Brien J,. 2002. Volumetric MRI study of the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. J Neurol Neurosurg Psychiatry 72: 406-407.
8. Beyer MK, Larsen JP, Aarsland D,. 2007. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 69: 747-754.
9. Bibl M, Mollenhauer B, Esselmann H, et al,. 2006. CSF amyloid-beta peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129: 1177-1187.
10. Bibl M, Mollenhauer B, Lewczuk P, et al,. 2007. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry 12: 671-680.
11. Bohnen NI, Kaufer DI, Ivanco LS, et al,. 2003. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60: 1745-1748.
12. Bostrom F, Hansson O, Gerhardsson L, et al,. 2009. CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies. Neurobiol Aging 30: 1265-1271.
13. Buerger K, Zinkowski R, Teipel S, et al,. 2002. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59: 1267-1272.
14. Buerger K, Ewers M, Pirttila T, et al,. 2006. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129: 3035-3041.
15. Burton EJ, Karas G, Paling SM, et al,. 2002. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 17: 618-630.
16. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT,. 2004. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 127: 791-800.
17. Ceravolo R, Volterrani D, Gambaccini G, et al,. 2003. Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease. Neurol Sci 24: 162-163.
18. 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. Neuroimage 33: 423-429.
19. 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies. Int Psychogeriatr 20: 1124-1140.
20. Colloby SJ, Firbank MJ, Pakrasi S, et al,. 2009. Alterations in nicotinic alpha4beta2 receptor binding in vascular dementia using I-123-5IA-85380 SPECT: comparison with regional cerebral blood flow. Neurobiol Aging 32: 293-301.
21. Cousins DA, Burton EJ, Burn D, et al,. 2003. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study. Neurology 61: 1191-1195.
22. Del Ser T, Hachinski V, Merskey H, Munoz DG,. 2001. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord 15: 31-44.
23. 18F]FDG PET study. Neurology 68: 501-508.
24. 11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79: 1331-1338.
25. 123I-MIBG) scintigraphy in Lewy body disorders. Neurologia 24: 170-176.
26. Estorch M, Camacho V, Paredes P, et al,. 2008. Cardiac I-123-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging 35: 1636-1641.
27. 18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol 191: S95-S103.
28. Gomez-Tortosa E, Gonzalo I, Fanjul S, et al,. 2003. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 60: 1218-1222.
29. Gomperts SN, Rentz DM, Moran E, et al,. 2008. Imaging amyloid deposition in Lewy body diseases. Neurology 71: 903-910.
30. Hanyu H, Shimizu S, Hirao K, et al,. 2006a. Differentiation of dementia with Lewy bodies from Alzheimer's disease using Mini-Mental State Examination and brain perfusion SPECT. J Neurol Sci 250: 97-102.
31. Hanyu H, Shimizu S, Hirao K, et al,. 2006b. The role of I-123-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement Geriatr Cogn Disord 22: 379-384.
32. Hanyu H, Shimizu S, Hirao K, et al,. 2006c. Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. Eur J Nucl Med Mol Imaging 33: 248-253.
33. Hort J, O'Brien JT, Gainotti G, et al,. 2010. and on behalf of the EFNS Scientist Panel on Dementia: EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 17: 1236-1248.
34. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 55: 1575-1577.
35. Ikonomovic MD, Klunk WE, Abrahamson EE, et al,. 2008. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131: 1630-1645.
36. Ishii K, Hosaka K, Mori T, Mori E,. 2004. Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies. Ann Nucl Med 18: 447-451.
37. Ishii K, Kanda T, Uemura T, et al,. 2009. Computer-assisted diagnostic system for neurodegenerative dementia using brain SPECT and 3D-SSP. Eur J Nucl Med Mol Imaging 36: 831-840.
38. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131: 665-680.
39. 131I-metaiodobenzylguanidine (MIBG) uptake (preliminary report). J Med Assoc Thai 87: 1176-1181.
40. Kashihara K, Ohno M, Kawada S, Okumura Y,. 2006. Reduced cardiac uptake and enhanced washout of I-123-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. J Nucl Med 47: 1099-1101.
41. Kasuga K, Tokutake T, Ishikawa A, et al,. 2010. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 81: 608-610.
42. Kemp PM, Hoffmann SA, Tossici-Bolt L, Fleming JS, Holmes C,. 2007. Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. Nucl Med Commun 28: 451-456.
43. Klunk WE, Mathis CA,. 2008. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol 21: 683-687.
44. Klunk WE, Engler H, Nordberg A, et al,. 2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319.
45. Kobayashi S, Tateno M, Morii H, Utsumi K, Saito T,. 2009. Decreased cardiac MIBG uptake, its correlation with clinical symptoms in dementia with Lewy bodies. Psychiatry Res 174: 76-80.
46. 11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement 4: S67-S76.
47. 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 50: 1638-1645.
48. Litvan I, Bhatia KP, Burn DJ, et al,. 2003. Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18: 467-486.
49. Lobotesis K, Fenwick JD, Phipps A, et al,. 2001. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 56: 643-649.
50. Lockhart A, Lamb JR, Osredkar T, et al,. 2007. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 130: 2607-2615.
51. McKeith I, Mintzer J, Aarsland D, et al,. 2004. DLB on behalf of the International Psychogeriatric Association Expert Meeting on DLB: dementia with Lewy bodies. Lancet Neurol 3: 19-28.
52. McKeith IG, Dickson DW, Lowe J, et al,. 2005. Consortium on DLB: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863-1872.
53. 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6: 305-313.
54. Middelkoop HA, Van der Flier WM, Burton EJ, et al,. 2001. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology 57: 2117-2120.
55. Miyamoto T, Miyamoto M, Suzuki K, et al,. 2008. I-123-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep 31: 717-723.
56. Mollenhauer B, Cepek L, Bibl M, et al,. 2005a. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 19: 164-170.
57. Mollenhauer B, Bibl M, Trenkwalder C, et al,. 2005b. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. J Neural Transm 112: 933-948.
58. Mollenhauer B, Bibl M, Wiltfang J, et al,. 2006. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 44: 192-195.
59. Mollenhauer B, Cullen V, Kahn I, et al,. 2008. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213: 315-325.
60. 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 49: 390-398.
61. Nagayama H, Hashimoto M, Ueda M, et al,. 2005. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 76: 249-251.
62. Namba H, Fukushi K, Nagatsuka S, et al,. 2002. Positron emission tomography: quantitative measurement of brain acetylcholinesterase activity using radiolabeled substrates. Methods 27: 242-250.
63. Noguchi-Shinohara M, Tokuda T, Yoshita M, et al,. 2009. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res 1251: 1-6.
64. Nordberg A,. 2008. Amyloid imaging in Alzheimer's disease. Neuropsychologia 46: 1636-1641.
65. 123I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD. Neurobiol Aging 31: 1903-1911.
66. O'Brien JT, Paling S, Barber R, et al,. 2001. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 56: 1386-1388.
67. O'Brien JT, Colloby S, Fenwick J, et al,. 2004. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61: 919-925.
68. O'Brien JT, Colloby SJ, Pakrasi S, et al,. 2007. Alpha4beta2 nicotinic receptor status in Alzheimer's disease using I-123-5IA-85380 single photon emission computed tomography. J Neurol Neurosurg Psychiatry 78: 356-361.
69. 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. Neuroimage 40: 1056-1063.
70. 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 194: 34-39.
71. 123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Intern Med 42: 686-690.
72. Parnetti L, Lanari A, Amici S, et al,. 2001. Phospho-Tau International Study Group: CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Neurol Sci 22: 77-78.
73. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 68: 1205-1212.
74. Rowe CC, Ng S, Ackermann U, et al,. 2007. Imaging beta-amyloid burden in aging and dementia. Neurology 68: 1718-1725.
75. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7: 129-135.
76. Sabri O, Gertz H, Dresel S, et al,. 2010. Multicentre phase 2 trial on florbetaben for β-amyloid brain PET in Alzhiemer's disease. J Nucl Med 51: 384.
77. Schultz K, Wiehager S, Nilsson K, et al,. 2009. Reduced CSF CART in dementia with Lewy bodies. Neurosci Lett 453: 104-106.
78. Shimada H, Hirano S, Shinotoh H, et al,. 2009. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73: 273-278.
79. Shimizu S, Hanyu H, Kanetaka H, et al,. 2005. Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT. Dement Geriatr Cogn Disord 20: 25-30.
80. Small GW, Kepe V, Ercoli LM, et al,. 2006. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355: 2652-2663.
81. Spiegel J,. 2010. Diagnosis and pathophysiological impact of myocardial MIBG scintigraphy in Parkinson's disease. Parkinson's Dis 2010: 1-6.
82. Spiegel J, Mollers MO, Jost WH, et al,. 2005. FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord 20: 552-561.
83. Spies PE, Melis RJ, Sjogren MJ, Rikkert MG, Verbeek MM,. 2009. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J Alzheimers Dis 16: 363-369.
84. Suzuki M, Kuriita A, Hashimoto M, et al,. 2006. Impaired myocardial I-123-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease. J Neurol Sci 240: 15-19.
85. Tam CWC, Burton EJ, McKeith IG, Burn DJ, O'Brien JT,. 2005. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 64: 861-865.
86. Tateno M, Kobayashi S, Shirasaka T, et al,. 2008. Comparison of the usefulness of brain perfusion SPECT and MIBG myocardial scintigraphy for the diagnosis of dementia with Lewy bodies. Dement Geriatr Cogn Disord 26: 453-457.
87. Tiraboschi P, Hansen LA, Alford M, et al,. 2000. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54: 407-411.
88. Tiraboschi P, Hansen LA, Alford M, et al,. 2002. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry 59: 946-951.
89. 18F]AH110690 as a biomarker of Alzheimer's disease-related brain amyloidosis. Alzheimers Dement 4: T308-T.
90. Vanderstichele H, De Vreese K, Blennow K, et al,. 2006. Analytical performance and clinical utility of the Innotest Phospho-Tau181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 44: 1472-1480.
91. Vanmechelen E, Vanderstichele H, Hulstaert F, et al,. 2001. Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. Mech Ageing Dev 122: 2005-2011.
92. 11C]SB-13 ""PET. Am J Geriatr Psychiatry 12: 584-595.
93. Wada-Isoe K, Kitayama M, Nakaso K, Nakashima K,. 2007. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci 260: 33-37.
94. Walker Z, Costa DC, Walker RW, et al,. 2002. Differentiation of dementia with Lewy bodies from Alzhiemer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73: 134-140.
95. Walker Z, Jaros E, Walker RW, et al,. 2007. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 78: 1176-1181.
96. 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 70: 781-783.
97. Watson R, Blamire AM, O'Brien JT,. 2009. Magnetic resonance imaging in Lewy body dementias. Dement Geriatr Cogn Disord 28: 493-506.
98. Whitwell JL, Weigand SD, Shiung MM, et al,. 2007a. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 130: 708-719.
99. Whitwell JL, Jack CR Jr, Parisi JE, et al,. 2007b. Rates of cerebral atrophy differ in different degenerative pathologies. Brain 130: 1148-1158.
100. Yong SW, Yoon JK, An YS, Lee PH,. 2007. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 14: 1357-1362.
101. 123I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzhiemer's type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 71: 583-588.